Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Subscribe To Our Newsletter & Stay Updated
